Michael W Drazer
Overview
Explore the profile of Michael W Drazer including associated specialties, affiliations and a list of published articles.
Author names and details appear as published. Due to indexing inconsistencies, multiple individuals may share a name, and a single author may have variations. MedLuna displays this data as publicly available, without modification or verification
Snapshot
Snapshot
Articles
36
Citations
451
Followers
0
Related Specialties
Related Specialties
Top 10 Co-Authors
Top 10 Co-Authors
Published In
Published In
Affiliations
Affiliations
Soon will be listed here.
Recent Articles
1.
Kindler H, Dagogo-Jack I, de Perrot M, Drazer M, Ismaila N, Hassan R
JCO Oncol Pract
. 2025 Mar;
:OP2500035.
PMID: 40053896
No abstract available.
2.
Kindler H, Ismaila N, Bazhenova L, Chu Q, Churpek J, Dagogo-Jack I, et al.
J Clin Oncol
. 2025 Jan;
43(8):1006-1038.
PMID: 39778125
Purpose: To provide evidence-based recommendations to practicing physicians and others on the management of pleural mesothelioma (PM). Methods: ASCO convened an Expert Panel of medical oncology, thoracic surgery, radiation oncology,...
3.
Zerella J, Homan C, Arts P, Lin X, Spinelli S, Venugopal P, et al.
Blood
. 2024 Jul;
144(17):1765-1780.
PMID: 38991192
The genomics era has facilitated the discovery of new genes that predispose individuals to bone marrow failure (BMF) and hematological malignancy (HM). We report the discovery of ETS-related gene (ERG),...
4.
Real world predictors of response and 24-month survival in high-grade TP53-mutated myeloid neoplasms
Kaur A, Rojek A, Symes E, Nawas M, Patel A, Patel J, et al.
Blood Cancer J
. 2024 Jun;
14(1):99.
PMID: 38890297
Current therapies for high-grade TP53-mutated myeloid neoplasms (≥10% blasts) do not offer a meaningful survival benefit except allogeneic stem cell transplantation in the minority who achieve a complete response to...
5.
Raeder H, Drazer M
Clin Cancer Res
. 2024 Apr;
30(14):2857-2859.
PMID: 38652676
Expansion of conventional dendritic cells via FMS-like tyrosine kinase 3 agonism has promising therapeutic potential in the treatment of advanced solid tumors. In this study, we discuss the results of...
6.
Roloff G, Kosuri S, Nawas M, DuVall A, Patel A, Riedell P, et al.
Haematologica
. 2024 Apr;
109(11):3739-3744.
PMID: 38618681
No abstract available.
7.
Bansal V, Mitchell O, Drazer M, Kindler H, Turaga K
Ann Surg Oncol
. 2024 Mar;
31(6):3785-3786.
PMID: 38502295
No abstract available.
8.
Madero-Marroquin R, Dworkin E, Weiner H, Saygin C, Nawas M, Drazer M, et al.
Leuk Lymphoma
. 2024 Mar;
65(6):864-867.
PMID: 38441062
No abstract available.
9.
Bansal V, Mitchell O, Bregio C, Witmer H, Dhiman A, Godley 4th F, et al.
Ann Surg Oncol
. 2024 Feb;
31(5):3339-3349.
PMID: 38372861
Introduction: Venous thromboembolism (VTE) is a common complication in patients with abdominal malignancies. Despite known associations between pleural mesothelioma and increased VTE risk, the characteristics of VTE in patients with...
10.
Mitchell O, Gilliam K, Del Gaudio D, McNeely K, Smith S, Acevedo M, et al.
JAMA Netw Open
. 2023 Aug;
6(8):e2327351.
PMID: 37556141
Importance: Patients with mesothelioma often have next-generation sequencing (NGS) of their tumor performed; tumor-only NGS may incidentally identify germline pathogenic or likely pathogenic (P/LP) variants despite not being designed for...